This special issue entitled "Application and Innovation of Multiomics Technologies in Clinical Oncology" compiled 43 articles, highlighting different applications and findings using genomics, transcriptomics and multiomics in a wide range of cancer types. One of the powerful and common omics'applications is its ability to identify molecular signatures and biomarkers for cancer classification, metastasis, prognosis and treatment. This special issue provides ample examples of such, including miR-139-5p and a 3-miRNA signature as potential biomarkers for subtyping breast carcinoma (Sun H et al., 2022 Mar 31;12:857714) and predicting survival in nasopharyngeal carcinoma (Zhou JH et al, 2022 Jan 27;11:823603), LncRNA-AC02278.4 and ASF1B as Prognostic Biomarkers for Tumor Growth and Metastasis in Lung Adenocarcinoma (Chen X et al., 2022 Apr 6;12:860961), and poor outcome in the HBV-infected hepatocellular carcinoma (Wang X et al., 2022 Feb 24;12:838845), immune-related and energy metablolism-related gene signatures with prognostic potential for pancreatic cancer (Chen R et al., 2022 Apr 27;12:841530) and hepatocellular carcinoma (Liu H et al., 2022 Sep 29;12:917897).Of particular interest, Huang ZL et al (2022 May 30;12:878923) used univariable Cox regression analyses and differential gene expression analysis with bulk RNAseq data to identify eight genes that are closely associated with the recurrence-free survivals (RFS) of HCC patients in both training and three validation cohorts. They subsequently built a multivariable Cox model based on the expression of these genes to predict the risk of HCC recurrence. The results showed that the Eight-Gene Cox (EGC) model outperformed other published models and could serve as independent predictor in predicting HCC recurrence. Furthermore, the authors investigated the cell-type-specific expression patterns and their biological functions of these eight marker genes in tumor microenvironment using single-cell RNA sequencing data. Interestingly, these genes had different expression patterns in different cell types. For example, PLCB1 and SLC22A7 were predominantly expressed in malignant cells while FASLG and IL2RB were specifically expressed in T cells, suggesting their functional roles in these given cell types.The results of this study are not only significant in terms of providing a novel model for HCC recurrence prediction but also in shedding light on the underlying mechanisms behind HCC recurrence. It demonstrates the importance of the tumor microenvironment and highlights the need for a more comprehensive understanding of the interplay between tumor cells and their surrounding microenvironment in cancer development and progression. The insights gained into the functional roles of the HCC recurrence marker genes provide clues for further research and the development of new therapeutic strategies for the treatment of HCC.In addition to gene expression signatures and biomarkers, the DNA markers are equally informative for predicting treatment efficacy, toxicity and clinical outcome. He K et al. (2022 Jul 14;12:928605) identified genetic determinants that can explain individual variations in radiosensitivity and radiotherapy-associated toxicity in 122 patients with unresectable stage III nonsmall-cell lung cancer (NSCLC). The research confirmed previously reported genetic association with clinical outcomes and also identified the FGFR family genes, MET, PTEN, and NOTCH2 as potential novel and independent risk factors of poor post-CRT survival by using a 474-cancer and radiotherapy-related gene panel. These novel biomarkers may offer new therapeutic targets for patients with NSCLC. The identification of genetic markers in relation to radiotherapyassociated thoracic toxicity is critical for the design of better treatment strategies to reduce or eliminate the risk of toxicities associated with CRT.This study has several important clinical implications. It demonstrated the clinical utility of focused NGS panels in identifying predictive biomarkers for response to CRT, reinforced the importance of pre-treatment genetic information to better inform CRT outcomes and clinical actions in stage III unresectable NSCLCs, and stressed that integrated analysis of multiple alterations can lead to improved stratification of the risk populations.The utilization of a multi-omics approach has also facilitated the comprehension of molecular pathways, mechanisms, and mechanistic models for tumor development by compiling various types of data and constructing new data-driven concepts. In this research topic, such efforts were documented and published for several common and rare cancers, including colon (Want Sh et al., 2022 Mar 15;12:857148.), gastric (Gao WC and Yang M, 2022 May 4;12:881015), bladder (Mao YP et al., 2022 Feb 25;12:835074), nasopharyngeal carcinoma (Lu X et al., 2022 Jul 26;12:965088), and adult spinal intramedullary astrocytomas (Konovalov N et al., 2022 Mar 21;12:837570), the latter paper is supplemented with the first-of-its-kind collection of experimental RNAseq profiles for this orphan cancer.As the field of omics continues to evolve and expand, a multiomics approach is becoming increasingly important for advancing our understanding of complex diseases such as cancer. By embracing a multiomics approach that combine and integrate multiple layers of molecular information, we can accelerate the pace of discovery and translation of omics research into clinical practice in cancer.
3 Authors
- YT
Yin Tian
Department of Pediatric Surgery, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, China
- LC
Li’e Chen
Department of Pathology, Sanya Central Hospital (Hainan Third People‘s Hospital), China
- YJ
Yun Jiang
Department of Ultrasound Diagnosis, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, China
10 Authors
- CL
Chaofeng Li
Gastrointestinal Surgery Department, China-Japan Friendship Hospital, China
- ZC
Zhengju Chen
Nanchang Institute of Technology, College of Medicine, China. Pooling Medical Research Institutes, China
- JG
Jinli Gao
Department of Pathology, East Hospital, Tongji University, China
- TT
Tao Tang
Gastrointestinal Surgery Department, China-Japan Friendship Hospital, China
- LZ
Lei Zhou
Gastrointestinal Surgery Department, China-Japan Friendship Hospital, China
- GZ
Guochao Zhang
Gastrointestinal Surgery Department, China-Japan Friendship Hospital, China
- DZ
Dongdong Zhang
Gastrointestinal Surgery, Peking University International Hospital, China
- CS
Chao Shen
Gastrointestinal Surgery, Peking University International Hospital, China
- LG
Lei Guo
Pooling Medical Research Institutes, Hangzhou, China
- TF
Tao Fu
Gastrointestinal Surgery Department, China-Japan Friendship Hospital, China
6 Authors
- MY
Meiling Yang
Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, China
- FW
Fen Wang
Pathologica Department, The First Affiliated Hospital of Sun Yat-Sen University, China
- GL
Guohao Lu
Key Laboratory of Stem Cells and Tissue Engineering (Sun Yat-Sen University), Ministry of Education, China
- MC
Mingzhe Cheng
Musculoskeletal Oncology Department, the First Affiliated Hospital of Sun Yat-Sen University, China
- WZ
Wei Zhao
Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, China
- CZ
Changye Zou
Musculoskeletal Oncology Department, the First Affiliated Hospital of Sun Yat-Sen University, China
4 Authors
- WL
Wenming Lv
Department of Neurology, Second Hospital of Lanzhou University, China
- LS
Lin Shi
Department of Hematology, Peking University International Hospital, China
- JP
Jiebing Pan
Department of General Surgery, Lanzhou University Second Hospital, China
- SW
Shengbao Wang
Emergency Center of the Second Hospital of Lanzhou University, China




